Satoshi Yuki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Satoshi Yuki has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
Atsushi Ohtsu
National Cancer Center Hospital East, Kashiwa, Japan
2 shared publications- Eiji Shinozaki
Department of Gastroenterological Chemotherapy, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo 135-8550, Japan
2 shared publications Gen Sobue
Brain and Mind Research Center Nagoya University Graduate School of Medicine Nagoya Japan
2 shared publicationsKaoru Ishizaki
Global Pharmacovigilance Department Mitsubishi Tanabe Pharma Corporation Tokyo Japan
2 shared publications- Kensei Yamaguchi
Gastroenterological Chemotherapy Department, The Cancer Institute Hospital of JFCR, Tokyo, Japan
2 shared publications - Kentaro Yamazaki
Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan
2 shared publications
Latest Publications
- Open Access
- 28 December 2024
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 182, 117792
Paraoxonase 1 ameliorates neurological symptoms and motor coordination impairment caused by cerebral ischemia-reperfusion injury
- 28 December 2024
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 182, 117792
Open AccessParaoxonase 1 ameliorates neurological symptoms and motor coordination impairment caused by cerebral ischemia-reperfusion injury
- Open Access
- 11 December 2023
- Published by Wiley in Neurology and Clinical Neuroscience
- Vol. 12 (2) , 95-99
Long‐term safety of oral edaravone in Japanese patients with amyotrophic lateral sclerosis: Sub‐analysis of a global, open‐label, phase 3 study
- 11 December 2023
- Published by Wiley in Neurology and Clinical Neuroscience
- Vol. 12 (2) , 95-99
Open AccessLong‐term safety of oral edaravone in Japanese patients with amyotrophic lateral sclerosis: Sub‐analysis of a global, open‐label, phase 3 study
- Open Access
- 13 February 2021
- Published by Wiley in Neurology and Clinical Neuroscience
- Vol. 9 (3) , 223-229
Real‐world safety of the novel, free radical scavenger edaravone for amyotrophic lateral sclerosis patients: Data from the post‐marketing surveillance SUNRISE Japan
Background: Treatment options for amyotrophic lateral sclerosis (ALS) are limited. SUNRISE Japan is an ongoing post‐marketing surveillance evaluating the long‐term efficacy and safety of edaravone, a novel neuroprotectant agent, and free radical scavenger, in patients with ALS.Aim: This study aims to describe the real‐word safety results of ALS patients enrolled in SUNRISE Japan.Methods: Patients diagnosed with ALS and prescribed edaravone for the first time during the surveillance period were included. Patients were prescribed edaravone according to the prescribing information. The incidence of adverse drug reactions (ADRs) reported up to 1 year of follow‐up was evaluated.Results: Of 805 patients enrolled up to April 2020, 800 were included in the safety analysis set. Patients had a mean age of 66.3 years, 55.1% were male, and they had a mean disease duration of 1.8 years. In total, 97 patients (12.1%) reported at least one ADR, with a total of 148 ADR events reported. Thirty patients (3.8%) reported at least one serious ADR with a total of 42 serious ADR events reported. Hepatic function abnormal was the most frequently reported ADR, with an incidence of 4.4% (35/800). A higher incidence of ADRs was observed in patients with percent forced vital capacity ≥80%, and those with previous/concomitant treatment with riluzole.Conclusion: In this surveillance study, hepatic ADRs were the most frequently reported events. These ADRs have also been reported previously in patients receiving standard therapy. No new safety concerns were raised with real‐world use of edaravone.
- 13 February 2021
- Published by Wiley in Neurology and Clinical Neuroscience
- Vol. 9 (3) , 223-229
Open AccessReal‐world safety of the novel, free radical scavenger edaravone for amyotrophic lateral sclerosis patients: Data from the post‐marketing surveillance SUNRISE Japan
Background: Treatment options for amyotrophic lateral sclerosis (ALS) are limited. SUNRISE Japan is an ongoing post‐marketing surveillance evaluating the long‐term efficacy and safety of edaravone, a novel neuroprotectant agent, and free radical scavenger, in patients with ALS.Aim: This study aims to describe the real‐word safety results of ALS patients enrolled in SUNRISE Japan.Methods: Patients diagnosed with ALS and prescribed edaravone for the first time during the surveillance period were included. Patients were prescribed edaravone according to the prescribing information. The incidence of adverse drug reactions (ADRs) reported up to 1 year of follow‐up was evaluated.Results: Of 805 patients enrolled up to April 2020, 800 were included in the safety analysis set. Patients had a mean age of 66.3 years, 55.1% were male, and they had a mean disease duration of 1.8 years. In total, 97 patients (12.1%) reported at least one ADR, with a total of 148 ADR events reported. Thirty patients (3.8%) reported at least one serious ADR with a total of 42 serious ADR events reported. Hepatic function abnormal was the most frequently reported ADR, with an incidence of 4.4% (35/800). A higher incidence of ADRs was observed in patients with percent forced vital capacity ≥80%, and those with previous/concomitant treatment with riluzole.Conclusion: In this surveillance study, hepatic ADRs were the most frequently reported events. These ADRs have also been reported previously in patients receiving standard therapy. No new safety concerns were raised with real‐world use of edaravone.
- Open Access
- 17 May 2020
- Published by Wiley in Neurology and Clinical Neuroscience
- Vol. 8 (5) , 261-269
Baseline characteristics of patients from ongoing post‐marketing surveillance, evaluating the real‐world efficacy and safety of edaravone, a novel, free radical scavenger, for amyotrophic lateral sclerosis patients in Japan (SUNRISE Japan)
Background: The ongoing SUNRISE Japan post‐marketing surveillance is collecting real‐world data about the long‐term efficacy and safety of edaravone in amyotrophic lateral sclerosis (ALS) for up to 5 years.Aim: To provide detailed methodologic information about SUNRISE Japan and report baseline data.Methods: Survival time, time to invasive tracheal intubation, other clinical events, ALS Functional Rating Scale‐Revised [ALSFRS‐R] scores, and safety will be assessed.Results: In total, 797 patients were included in the safety and efficacy analysis sets; 55.3% were male, two‐thirds of patients were aged ≥65 years, and 86.1% had a body mass index of 2. Disease duration was <1 year (37.3% of patients), or 1‐2 years (32.1%). Disease severity (Japan ALS severity classification) included grade 2 (42.0% of patients), grade 3 (28.5%), or grade 1 (15.7%). Most ALS cases were sporadic (96.4% of patients). The most common site of symptom onset was the upper limbs (43.5% of patients). ALS diagnosis (El Escorial revised Airlie House criteria) was definite (34.5% of patients), probable (36.1%), probable supported by laboratory data (19.4%), possible (6.4%), or suspected (3.5%). The mean ALSFRS‐R score was 38.5, and mean percent forced vital capacity, 83.6%. Over 60% of patients had been treated with riluzole, and over 60% were receiving other concomitant drugs. Complications were noted in two‐thirds of patients.Conclusion: Data from the SUNRISE Japan study are expected to extend ALS knowledge in Japan and worldwide, and the study methodology may provide a model for other long‐term surveillance studies in neurodegenerative diseases.
- 17 May 2020
- Published by Wiley in Neurology and Clinical Neuroscience
- Vol. 8 (5) , 261-269
Open AccessBaseline characteristics of patients from ongoing post‐marketing surveillance, evaluating the real‐world efficacy and safety of edaravone, a novel, free radical scavenger, for amyotrophic lateral sclerosis patients in Japan (SUNRISE Japan)
Background: The ongoing SUNRISE Japan post‐marketing surveillance is collecting real‐world data about the long‐term efficacy and safety of edaravone in amyotrophic lateral sclerosis (ALS) for up to 5 years.Aim: To provide detailed methodologic information about SUNRISE Japan and report baseline data.Methods: Survival time, time to invasive tracheal intubation, other clinical events, ALS Functional Rating Scale‐Revised [ALSFRS‐R] scores, and safety will be assessed.Results: In total, 797 patients were included in the safety and efficacy analysis sets; 55.3% were male, two‐thirds of patients were aged ≥65 years, and 86.1% had a body mass index of 2. Disease duration was <1 year (37.3% of patients), or 1‐2 years (32.1%). Disease severity (Japan ALS severity classification) included grade 2 (42.0% of patients), grade 3 (28.5%), or grade 1 (15.7%). Most ALS cases were sporadic (96.4% of patients). The most common site of symptom onset was the upper limbs (43.5% of patients). ALS diagnosis (El Escorial revised Airlie House criteria) was definite (34.5% of patients), probable (36.1%), probable supported by laboratory data (19.4%), possible (6.4%), or suspected (3.5%). The mean ALSFRS‐R score was 38.5, and mean percent forced vital capacity, 83.6%. Over 60% of patients had been treated with riluzole, and over 60% were receiving other concomitant drugs. Complications were noted in two‐thirds of patients.Conclusion: Data from the SUNRISE Japan study are expected to extend ALS knowledge in Japan and worldwide, and the study methodology may provide a model for other long‐term surveillance studies in neurodegenerative diseases.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , TPS3632
A multicenter phase I/II study of TAS-102 with nintedanib in patients (pts) with metastatic colorectal cancer (mCRC) refractory to standard therapies (N-TASK FORCE): EPOC1410.
TPS3632 Background: In a RECOURSE phase III study, TAS-102 significantly improved progression-free survival (PFS) and overall survival (OS) over placebo in patients (pts) with metastatic colorectal cancer (mCRC) refractory to standard therapies. We reported the combination of TAS-102 with bevacizumab (C-TASK FORCE trial) showed promising anti-tumor activities with mild toxicities (Kuboki Y, et al. ASCO 2015). Nintedanib is a triple angiokinase inhibitor of vascular endothelial growth factor receptors (1,2,3), platelet-derived growth factor receptors (a, β), and fibroblast growth factor receptors (1,2,3). A global phase III study, called as the LUME-Colon 1, comparing nintedanib monotherapy versus placebo in pts with mCRC refractory to standard therapies is ongoing, on the basis of promising anti-tumor activities with mild toxicities in a phase I clinical study of nintedanib monotherapy (Mross et al.). Therefore, we initiated phase I/II study to assess efficacy and safety for the combination of TAS-102 with nintedanib. Methods: The key eligibility criteria were pts with mCRC refractory or intolerant to fluoropyrimidine, irinotecan, oxaliplatin, anti-angiogenesis inhibitor and anti-EGFR antibody (if wild-type RAS) and without prior regorafenib and TAS-102; at least one measurable lesion; and ECOG performance status of 0 or 1. Phase I part was designed to determine the recommended phase II dose (RP2D) in a “3+3” cohort-based dose escalation design of nintedanib (150mg BID every day on level 1 and 200mg BID every day on level 2) with a fixed dose of TAS-102 (35 mg/m2 BID on days 1–5 and 8–12 q4w). Primary endpoint of the phase II part was an investigator-assessed PFS rate at 16 weeks in pts receiving the combination with RP2D. Using a single stage binomial design, this study required 52 pts, with an investigator-assessed PFS rate at 16 weeks of 40% deemed promising and 25% unacceptable (one-sided alpha = 0.1; beta = 0.2). Secondary endpoints included OS, PFS, objective response rate, disease control rate, safety, and pharmacokinetic parameters. The enrollment to phase II part began in January 2016. Clinical trial information: UMIN000017114. Clinical trial information: 000017114.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , TPS3632
A multicenter phase I/II study of TAS-102 with nintedanib in patients (pts) with metastatic colorectal cancer (mCRC) refractory to standard therapies (N-TASK FORCE): EPOC1410.
TPS3632 Background: In a RECOURSE phase III study, TAS-102 significantly improved progression-free survival (PFS) and overall survival (OS) over placebo in patients (pts) with metastatic colorectal cancer (mCRC) refractory to standard therapies. We reported the combination of TAS-102 with bevacizumab (C-TASK FORCE trial) showed promising anti-tumor activities with mild toxicities (Kuboki Y, et al. ASCO 2015). Nintedanib is a triple angiokinase inhibitor of vascular endothelial growth factor receptors (1,2,3), platelet-derived growth factor receptors (a, β), and fibroblast growth factor receptors (1,2,3). A global phase III study, called as the LUME-Colon 1, comparing nintedanib monotherapy versus placebo in pts with mCRC refractory to standard therapies is ongoing, on the basis of promising anti-tumor activities with mild toxicities in a phase I clinical study of nintedanib monotherapy (Mross et al.). Therefore, we initiated phase I/II study to assess efficacy and safety for the combination of TAS-102 with nintedanib. Methods: The key eligibility criteria were pts with mCRC refractory or intolerant to fluoropyrimidine, irinotecan, oxaliplatin, anti-angiogenesis inhibitor and anti-EGFR antibody (if wild-type RAS) and without prior regorafenib and TAS-102; at least one measurable lesion; and ECOG performance status of 0 or 1. Phase I part was designed to determine the recommended phase II dose (RP2D) in a “3+3” cohort-based dose escalation design of nintedanib (150mg BID every day on level 1 and 200mg BID every day on level 2) with a fixed dose of TAS-102 (35 mg/m2 BID on days 1–5 and 8–12 q4w). Primary endpoint of the phase II part was an investigator-assessed PFS rate at 16 weeks in pts receiving the combination with RP2D. Using a single stage binomial design, this study required 52 pts, with an investigator-assessed PFS rate at 16 weeks of 40% deemed promising and 25% unacceptable (one-sided alpha = 0.1; beta = 0.2). Secondary endpoints included OS, PFS, objective response rate, disease control rate, safety, and pharmacokinetic parameters. The enrollment to phase II part began in January 2016. Clinical trial information: UMIN000017114. Clinical trial information: 000017114.
- 20 January 2015
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 33 (3_suppl) , 573
Clinical impact of expanded BRAF mutational status on the outcome for metastatic colorectal cancer patients with anti-EGFR antibody: An analysis of the BREAC trial (Biomarker Research for Anti-EGFR Monoclonal Antibodies by Comprehensive Cancer Genomics).
573 Background: BRAFV600E mutation has been recognized as a prognostic marker in patients (pts) with metastatic colorectal cancer (mCRC). Several studies have consistently shown a significant association between the presence of BRAFV600E mutation and resistance to anti-EGFR antibody therapy in pts with previously treated mCRC while there are few reports on the clinical impact of minor BRAF mutations. Methods: The BREAC trial was a multicenter, retrospective study to investigate the novel biomarkers of anti-EGFR antibody therapy. RAS and BRAF mutations were detected by targeted sequencing using FFPE materials of mCRC pts who received anti-EGFR antibody after a failure to standard therapies. Progression-free survival (PFS), overall survival (OS), and response rate (RR) were evaluated according to expanded RAS/BRAF mutational status. Results: Of 184 pts enrolled in the study, RAS/BRAF testing was succeeded in 150 pts. Patients characteristics were as follows; male/female 87/63, median age 63.5 years (range, 28-85), PS 0/1/2 81/65/4. Median PFS, OS, and RR were 4.0 months, 12.4 months, and 21%, respectively. Expanded RAS and BRAF mutations were detected in 40 pts (26.7%, KRAS/NRAS 29/11) and in 16 pts (10.7%, BRAFV600E/other 9/7), respectively. Observed BRAF mutations other than BRAFV600E were located at kinase domain. The clinical outcomes of other BRAF mutations were worse similar to those of BRAFV600E and expanded RAS mutations (Table). Conclusions: Expanded BRAF mutations might predict a lack of response for mCRC pts who received anti-EGFR antibody. Further investigation is warranted to confirm the clinical impact of expanded BRAF mutations. [Table: see text]
- 20 January 2015
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 33 (3_suppl) , 573
Clinical impact of expanded BRAF mutational status on the outcome for metastatic colorectal cancer patients with anti-EGFR antibody: An analysis of the BREAC trial (Biomarker Research for Anti-EGFR Monoclonal Antibodies by Comprehensive Cancer Genomics).
573 Background: BRAFV600E mutation has been recognized as a prognostic marker in patients (pts) with metastatic colorectal cancer (mCRC). Several studies have consistently shown a significant association between the presence of BRAFV600E mutation and resistance to anti-EGFR antibody therapy in pts with previously treated mCRC while there are few reports on the clinical impact of minor BRAF mutations. Methods: The BREAC trial was a multicenter, retrospective study to investigate the novel biomarkers of anti-EGFR antibody therapy. RAS and BRAF mutations were detected by targeted sequencing using FFPE materials of mCRC pts who received anti-EGFR antibody after a failure to standard therapies. Progression-free survival (PFS), overall survival (OS), and response rate (RR) were evaluated according to expanded RAS/BRAF mutational status. Results: Of 184 pts enrolled in the study, RAS/BRAF testing was succeeded in 150 pts. Patients characteristics were as follows; male/female 87/63, median age 63.5 years (range, 28-85), PS 0/1/2 81/65/4. Median PFS, OS, and RR were 4.0 months, 12.4 months, and 21%, respectively. Expanded RAS and BRAF mutations were detected in 40 pts (26.7%, KRAS/NRAS 29/11) and in 16 pts (10.7%, BRAFV600E/other 9/7), respectively. Observed BRAF mutations other than BRAFV600E were located at kinase domain. The clinical outcomes of other BRAF mutations were worse similar to those of BRAFV600E and expanded RAS mutations (Table). Conclusions: Expanded BRAF mutations might predict a lack of response for mCRC pts who received anti-EGFR antibody. Further investigation is warranted to confirm the clinical impact of expanded BRAF mutations. [Table: see text]
- 26 January 2011
- Published by Elsevier in Brain Research
- Vol. 1382, 321-325
Feasibility study for functional test battery of SOD transgenic rat (H46R) and evaluation of edaravone, a free radical scavenger
- 26 January 2011
- Published by Elsevier in Brain Research
- Vol. 1382, 321-325
Feasibility study for functional test battery of SOD transgenic rat (H46R) and evaluation of edaravone, a free radical scavenger
- Open Access
- 1 January 2007
- Published by S. Karger AG in Pathophysiology of Haemostasis and Thrombosis
- Vol. 36 (5) , 245-250
Effects of Alteplase, a Thrombolytic Agent, in a Rat Photothrombotic Middle Cerebral Artery Occlusion Model
In this study, we examined the effects of alteplase, a recombinant tissue-type plasminogen activator (t-PA), in a simple and reproducible rat middle cerebral artery (MCA) occlusion model induced by photoillumination with 12 mg/kg of rose bengal. A clinically equivalent dose of alteplase (3 mg/kg), which was administered just after thrombotic occlusion of the MCA, significantly reopened the thrombotic MCA occlusion in 16 of 23 animals (69.6%) when compared with vehicle-treated animals (8 of 22 animals, 36.4%). In addition, alteplase significantly reduced cerebral damage and improved neurological deficits. Although it has been reported that t-PA possesses neurotoxicity, the present findings suggest that alteplase was effective in a rat acute stroke model due to reopening of thrombotic MCA occlusion. This new model is very useful for investigating the efficacy of thrombolytic agents in stroke research, providing a condition similar to the clinical setting.
- 1 January 2007
- Published by S. Karger AG in Pathophysiology of Haemostasis and Thrombosis
- Vol. 36 (5) , 245-250
Open AccessEffects of Alteplase, a Thrombolytic Agent, in a Rat Photothrombotic Middle Cerebral Artery Occlusion Model
In this study, we examined the effects of alteplase, a recombinant tissue-type plasminogen activator (t-PA), in a simple and reproducible rat middle cerebral artery (MCA) occlusion model induced by photoillumination with 12 mg/kg of rose bengal. A clinically equivalent dose of alteplase (3 mg/kg), which was administered just after thrombotic occlusion of the MCA, significantly reopened the thrombotic MCA occlusion in 16 of 23 animals (69.6%) when compared with vehicle-treated animals (8 of 22 animals, 36.4%). In addition, alteplase significantly reduced cerebral damage and improved neurological deficits. Although it has been reported that t-PA possesses neurotoxicity, the present findings suggest that alteplase was effective in a rat acute stroke model due to reopening of thrombotic MCA occlusion. This new model is very useful for investigating the efficacy of thrombolytic agents in stroke research, providing a condition similar to the clinical setting.